// App-Quantinova.ai

4584 : Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

Researchers

Presenter

  • Martin Boegemann

Principal Investigators

  • Jens Bedke

  • Martin Schostak

  • Manfred Welslau

  • Christiane Hering-Schubert

  • Thomas Wolf

  • Jan Schleicher

  • Alexander Petzold

  • Christian Doehn

  • Carsten Grullich

  • Viktor Grunwald

  • Thomas Steiner

  • Rainer Ehness

  • Dunja Klein

  • Tanja Medinger

  • Peter-Juergen Goebell

Medical Centers

  • University of Muenster Medical Center, Munster, Germany

  • Department of Urology, University Tubingen, Tubingen, Germany

  • University of Magdeburg, Magdeburg, Germany

  • Hematological-Oncological Practice Altona, Hamburg, Germany

  • St. Georg Klinikum Eisenach, Eisenach, Germany

  • Hamatologie & Intern. Onkologie, Gemeinschaftspraxis Hamatologie - Onkologie, Dresden, Germany

  • Katharinenhospital, Stuttgart, Germany

  • GP Dres. Wilke/Wagner/Petzoldt, Hamatologie/Onkologie, Furth, Germany

  • Urologikum Lubeck, Lubeck, Germany

  • University Clinic Heidelberg, Heidelberg, Germany

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Helios-Klinikum Erfurt, Klinik fur Urologie, Erfurt, Germany

  • Novartis Pharma GmbH, Nuernberg, Germany

  • Molecular Medicine, IOMEDICO AG, Freiburg, Germany

  • Statistics, IOMEDICO AG, Freiburg, Germany

  • University of Erlangen-Nuernberg, Erlangen, Germany

Locations

  • Germany

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Lenvatinib

  • Nivolumab

  • Pazopanib

Outcome

  • Unknown

Study Design

  • Non Interventional

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved